ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

perfluorohexyloctane

Also written as “NOV03”, “Miebo” and “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”.

Its studies are mostly in Dry Eye Syndromes, led by 2 companies.

Drug pagePerfluorohexyloctane: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 19, 202311 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companiesits history only101 open or runningphase 4since Jan 19, 2023Oct 23, 2019none ahead
Novaliq10 open or runningphase 2since Nov 2, 2017Nov 2, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novaliq only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2017First study: phase 2 study in Dry Eye SyndromesFirst studyNCT03333057 · 336 enrolled · United States
  2. Aug 6, 2023Named perfluorohexyloctaneINNProposed as its International Nonproprietary Name in WHO's List 129

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Novaliq leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03333057Dry Eye Syndromes · United States2CompletedMay 18, 2018336

How it is read

Names in the registry

  • “NOV03”, 4 entries
  • “Miebo”, 3 entries
  • “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”, 1 entry
  • “Perfluorohexyloctane ophthalmic solution”, 1 entry
  • “Lifitegrast/perfluorohexyloctane (PFHO)”, 1 entry

Codes read as this program: NOV03.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.